2.70
+0.28(+11.57%)
Currency In USD
| Previous Close | 2.42 |
| Open | 2.48 |
| Day High | 2.76 |
| Day Low | 2.44 |
| 52-Week High | 4.74 |
| 52-Week Low | 0.95 |
| Volume | 5.72M |
| Average Volume | 4.67M |
| Market Cap | 46.52M |
| PE | -0.36 |
| EPS | -7.58 |
| Moving Average 50 Days | 3.03 |
| Moving Average 200 Days | 3.34 |
| Change | 0.28 |
If you invested $1000 in Mural Oncology plc (MURA) since IPO date, it would be worth $710.53 as of April 19, 2025 at a share price of $2.7. Whereas If you bought $1000 worth of Mural Oncology plc (MURA) shares 1 year ago, it would be worth $756.3 as of April 19, 2025 at a share price of $2.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mural Oncology Announces Plans to Explore Strategic Alternatives
GlobeNewswire Inc.
Apr 15, 2025 12:00 PM GMT
Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144.4 million in cash as of December 31, 2024, Mural p
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
GlobeNewswire Inc.
Mar 25, 2025 10:30 AM GMT
Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis Continued demonstration of favorable tolerability profile generally consistent with previously reported
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewswire Inc.
Feb 18, 2025 12:00 PM GMT
WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting cytokine pathways, today announced that CEO Car
Data not available